• 1. Probing the substrate specificity of Trypanosoma brucei GlcNAc-PI de-N-acetylase with synthetic substrate analogues
  Amy S. Capes,Arthur Crossman,Michael D. Urbaniak,Sophie H. Gilbert,Michael A. J. Ferguson,Ian H. Gilbert Org. Biomol. Chem. 2014 12 1919

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzylethers

Chemical Profile of (1R,2R)-2-(Benzyloxy)cyclohexanamine and CAS No. 216394-06-8

The compound (1R,2R)-2-(Benzyloxy)cyclohexanamine, identified by the CAS number CAS No. 216394-06-8, is a significant molecule in the field of pharmaceutical chemistry and bioorganic synthesis. This amine derivative exhibits a unique structural configuration that makes it a valuable intermediate in the development of various therapeutic agents. Its chiral center and the presence of a benzyloxy group contribute to its diverse chemical reactivity, which has been extensively explored in recent years.

In recent years, the pharmaceutical industry has shown increasing interest in chiral amines due to their role in the synthesis of enantiomerically pure drugs. The stereochemistry of (1R,2R)-2-(Benzyloxy)cyclohexanamine plays a crucial role in determining its biological activity and pharmacokinetic properties. This compound has been studied for its potential applications in the development of central nervous system (CNS) drugs, where precise stereochemical control is essential for efficacy and safety.

The benzyloxy group in (1R,2R)-2-(Benzyloxy)cyclohexanamine serves as a key functional moiety that can be modified through various chemical transformations. This flexibility allows for the synthesis of a wide range of derivatives with tailored properties, making it a versatile building block in medicinal chemistry. Researchers have leveraged this compound to develop novel scaffolds for small-molecule drugs, particularly those targeting neurological disorders.

One of the most compelling aspects of (1R,2R)-2-(Benzyloxy)cyclohexanamine is its role in the synthesis of GABA receptor modulators. Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that plays a critical role in regulating neuronal excitability. Modulators of GABA receptors have been widely used to treat conditions such as anxiety, epilepsy, and sleep disorders. The chiral amine structure of this compound allows for selective interaction with GABA receptors, leading to improved therapeutic outcomes.

Recent studies have also highlighted the potential of (1R,2R)-2-(Benzyloxy)cyclohexanamine as a precursor in the synthesis of kinase inhibitors. Kinases are enzymes that play a central role in many cellular processes, including cell growth, differentiation, and signal transduction. Dysregulation of kinase activity is associated with various diseases, including cancer. By incorporating this compound into drug design strategies, researchers have been able to develop potent and selective kinase inhibitors with significant therapeutic potential.

The chemical synthesis of (1R,2R)-2-(Benzyloxy)cyclohexanamine has been optimized to ensure high yield and enantioselectivity. Advanced synthetic techniques, such as asymmetric hydrogenation and enzymatic resolution, have been employed to achieve the desired stereochemical purity. These methods not only enhance the efficiency of production but also minimize waste generation, aligning with green chemistry principles.

In addition to its pharmaceutical applications, (1R,2R)-2-(Benzyloxy)cyclohexanamine has found utility in materials science and industrial chemistry. Its unique structural features make it suitable for use as a chiral ligand in catalytic processes and as an intermediate in the production of specialty chemicals. The compound's stability under various reaction conditions further enhances its industrial relevance.

The future prospects for (1R,2R)-2-(Benzyloxy)cyclohexanamine are promising, with ongoing research exploring new synthetic pathways and applications. Collaborative efforts between academia and industry are expected to drive innovation in this field, leading to the development of novel therapeutics and advanced materials. As our understanding of molecular interactions continues to evolve, compounds like this will play an increasingly important role in addressing complex scientific challenges.

• 98454-39-8(trans-4-(Benzyloxy)cyclohexanamine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)